Search results
Results from the WOW.Com Content Network
Logo: SAMHSA's National Registry of Evidence-based Programs and Practices (NREPP), www.nrepp.samhsa.gov. In the behavioral health field, there is an ongoing need for researchers, developers, evaluators, and practitioners to share information about what works to improve outcomes among individuals coping with, or at risk for, mental disorders and substance abuse.
The Substance Abuse and Mental Health Services Administration (SAMHSA; pronounced / ˈ s æ m s ə /) is a branch of the U.S. Department of Health and Human Services.SAMHSA is charged with improving the quality and availability of treatment and rehabilitative services in order to reduce illness, death, disability, and the cost to society resulting from substance abuse and mental illnesses.
It replaced four earlier grant programs legislated by the Community Mental Health Centers Act, Mental Health Systems Act, Comprehensive Alcohol Abuse and Alcoholism Prevention, Treatment and Rehabilitation Act and Drug Abuse Prevention and Treatment Act. [2]
Treatment Improvement Protocols (TIPs) are a series of best-practice manuals for the treatment of substance use and other related disorders.The TIP series is published by the Substance Abuse and Mental Health Services Administration (SAMHSA), an operational division of the U.S. Department of Health and Human Services.
CCBHCs began in 2017 in eight states in a demonstration program following the passage of the Excellence in Mental Health Care Act, which was part of the Protecting Access to Medicare Act of 2014. [ 2 ] [ 5 ] [ 6 ] Over 500 CCBHCs are operating across the US in every state except Delaware, North Dakota, South Dakota, and South Carolina.
Drug rehabilitation is the process of medical or psychotherapeutic treatment for dependency on psychoactive substances such as alcohol, prescription drugs, and street drugs such as cannabis, cocaine, heroin, and amphetamines.
As doctors face scrutiny from the DEA, states have imposed even greater regulations severely limiting access to the medications, according to a 2014 report commissioned by the federal agency SAMHSA. Eleven state Medicaid programs put lifetime treatment limits on how long addicts can be prescribed Suboxone, ranging between one and three years.
At that time, responsibility for the DAWN and NHSDA programs were transferred to the Substance Abuse and Mental Health Services Administration (SAMHSA). NIDA is organized into divisions and offices, each of which is involved with programs of drug abuse research. Nora Volkow, MD, has been the director of NIDA since 2003. [3] According to NIH: